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Abstract
Background: There is increasing interest in the role of pro-inflammatory cytokines in the pathogenesis of sciatica
and whether these could be potential targets for treatment. We sought to investigate serum biomarker levels in
patients with low back-related leg pain, including sciatica.
Methods: Primary care consulters aged > 18 with low back-related leg pain were recruited to a cohort study (ATLAS).
Participants underwent a standardised clinical assessment, lumbar spine MRI and a subsample (n = 119) had samples
taken for biomarker analysis. Participants were classified having: a) clinically confirmed sciatica or referred leg pain, and
then subdivided into those with (or without) MRI confirmed nerve root compression due to disc prolapse. Seventeen
key cytokines, chemokines and matrix metalloproteinases (MMPs) implicated in sciatica pathogenesis including TNFα
and IL-6, were assayed in duplicate using commercial multiplex detection kits and measured using a Luminex
suspension array system. Median biomarker levels were compared between the groups using a Mann Whitney U test.
Multivariate logistic regression analysis was used to investigate the association between clinical measures and
biomarker levels adjusted for possible confounders such as age, sex, and symptom duration.
Results: No difference was found in the serum level of any of the 17 biomarkers tested in patients with (n = 93) or
without (n = 26) clinically confirmed sciatica, nor between those with (n = 44) or without (n = 49) sciatica and MRI
confirmed nerve root compression.
Conclusion: In this cohort, no significant differences in serum levels of TNFα, IL-6 or any other biomarkers were seen
between patients with sciatica and those with back pain with referred leg pain. These results suggest that in patients
with low back-related leg pain, serum markers associated with inflammation do not discriminate between patients with
or without clinically confirmed sciatica or between those with or without evidence of nerve root compression on MRI.
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Background
Lumbar spinal radicular pain (with or without radi-
culopathy) or sciatica, represents one distinct presen-
tation of low back-related leg pain, which is often
characterised by pain radiating to below the knee
and into the foot. Patients with sciatica suffer more
severe pain and disability and take longer to recover
than those with low back pain (LBP) alone [1]. Al-
though traditionally initially thought to be caused by
mechanical nerve root compression, usually by a
herniated disc, studies suggest inflammation (medi-
ated by cytokines) also contributes to the pathogen-
esis of sciatica [2].
Interest on possible inflammatory aetiologies for sci-
atica initially focused on the cytokine TNFα, including
randomised trials of anti-TNF inhibitors infliximab [3]
and adalumimab [4], showing some improvement in
leg pain and reduction in numbers of patients need-
ing spinal surgery [4], with meta-analyses suggesting
further trials are warranted [5–7]. These therapies
may represent a novel way to treat sciatica but are
expensive, and given that sciatica is common, data is
required to effectively target these drugs at patients
more likely to derive benefit.
Other pro-inflammatory cytokines investigated in-
clude IL-6- with studies showing high levels of IL-6
in disc samples from patients undergoing surgery [8].
A study by Pederson et al. [9] showed higher serum
levels of IL-6 and IL-8 in patients with persistent sci-
atic pain, defined as pain levels on a Visual Analogue
Score (VAS) of > 3, compared to those with pain
levels on VAS of < 3 at 12 months. A second study by
Wang et al. [10] also showed higher levels of IL-6,
IL-8, TNFα and IL-4 in patients with severe sciatica
(defined as pain VAS > 3) compared to those with
mild sciatica (VAS < 3) or healthy controls. However
patients with severe sciatica had a long duration of
symptoms (mean (SD) duration 48 (28.96) weeks) and
were recruited from a secondary care spinal clinic
and thus it is not clear whether these elevated bio-
marker levels represent patients with chronic or
severe symptoms or whether these biomarker levels
are elevated in a less selected population. Such an ap-
proach would help further elucidate whether these
biomarkers are elevated early in the symptom course
or could be used in predicting outcome or guide
treatment for sciatic pain.
Therefore, the aim of this study was to examine
serum levels of key biomarkers in patients presenting
in primary care with symptoms of low back-related leg
pain including sciatica, and to see whether levels were
different in patients with clinically diagnosed sciatica
with or without or evidence of nerve root compression
on MRI.
Methods
Participants
Primary care consulters aged > 18 with low back-related
leg pain were recruited as part of a longitudinal study
(the ATLAS study) investigating the overall prognosis
of low back-related leg pain and sciatica in primary
care. The ATLAS study procedures have been de-
scribed in detail elsewhere [11], here we give brief
information on recruitment and assessment details.
Patients consulting their GP (General Practitioner)
low back and leg pain, who were potentially eligible
for the ATLAS study, were sent a letter with informa-
tion about the study, an invitation to attend the re-
search clinic, and baseline questionnaires capturing
sociodemographic, pain, psychological and health vari-
ables. Patients with other inflammatory conditions,
such as rheumatoid arthritis were excluded. At the
research clinic, patients underwent a standardised
clinical assessment by one of seven experienced mus-
culoskeletal physiotherapists, and were diagnosed as
having clinically defined sciatica (spinal nerve root in-
volvement) or referred (non-specific) leg pain, based
on the examiner’s clinical opinion. Providing there
were no clinical contraindications to the procedure,
patients had a lumbar spine magnetic resonance im-
aging (MRI) scan within 2 weeks of their baseline as-
sessment. The MRI findings were not part of the
clinical diagnosis of sciatica or referred leg pain. All
MRIs were scored by a single assessor, a senior con-
sultant musculoskeletal radiologist. The assessor pro-
vided a clinical report indicating the presence/absence
of definite or possible nerve root compression by
lumbar spinal level (3 lower lumbar levels) and side
(right/left) and the reason(s) for it if present (e.g. disc
prolapse, stenosis) as per normal practice in radio-
logical reporting.
For the purposes of this nested study (which for
practical considerations, i.e. availability of phlebot-
omy service and storage for blood samples, could
only be conducted at a single research site), patients
consenting to the main study at this site, were also
invited to take part in the biomarker sub study.
Consenting patients had serum samples taken for
biomarker analysis in addition to the standardised
clinical assessment.
Participants were classified as having nerve root in-
volvement due to suspected disc prolapse on the basis of
the clinical assessment (clinically defined: yes/no).
For the purposes of analysis, we first examined levels
of serum biomarkers between patients with clinically
diagnosed disc-related sciatica and with referred leg
pain, and secondly we examined levels of serum bio-
markers between patients with clinically diagnosed
disc-related nerve root involvement and evidence of
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concordant MRI findings, and those patients without
evidence of concordant MRI findings.
All patients provided written informed consent. The bio-
marker study was approved by the North West- Greater
Manchester South Research Ethics Committee (REC refer-
ence number: 12/NW/0173).
Measurement of cytokines, chemokines and MMPs
Sera were separated from bloods collected in plain BD
Vacutainer® tubes at study entry. All sera were stored at -70o
C until required. Key cytokines, chemokines and matrix
metalloproteinases (MMPs) implicated in sciatica pathogen-
esis including TNFα, IL-1, IL-6, MMP1,3,8, aggregan and
monocyte chemoattractant protein-1 (MCP-1/CCL-2) were
measured in duplicate on a Bio-Plex™ 200 suspension array
system using commercially available multiplex detection kits
for cytokines (Milliplex multi-analyte profiling (MAP) kits,
Millipore (UK) Ltd., Walford, Hertfordshire, UK), or Fluoro-
kine MAP kits for MMPs (R&D Systems Europe, Abingdon,
Oxfordshire, UK). Further details on the kits used are
available in the Appendix. All assays were carried out
according to the manufacturers’ instructions. High and
low control samples were used in each assay.
Statistical analysis
All data were tested for normality and the appropriate
parametric or non-parametric test was selected for ana-
lysis. Initial univariable analysis was carried out using
the Mann Whitney U test to compare median cytokine
levels between groups. A multivariate variable selection
procedure using the algorithm of McHenry [12] was
used to select biomarker variables which showed the
strongest association with either clinically determined
sciatica, with/without MRI evidence of nerve root com-
pression. Multivariate logistic regression analysis was
used to investigate the association between clinical mea-
sures and biomarker levels while adjusting for possible
confounders such as age, sex, and symptom duration.
Statistical analyses were carried out using Number
Cruncher Statistical Software package for Windows
(NCSS 2000, NCSS Statistical Software, Kaysville, Utah,
USA). The significance level was set at a p value of 0.05.
Results
Data for the main ATLAS cohort are published else-
where [13]. One hundred nineteen patients were re-
cruited to the biomarker sub study, of these 73 (61.2%)
Table 1 Comparison of key characteristics for patients clinically diagnosed with or without sciatica. All figures are frequencies
(percentages) unless stated otherwise as mean (SD)
Characteristics Clinically defined sciatica
n = 93
Referred pain
n = 26
MRI + ve
(n = 44)
MRI –ve
(n = 49)
Socio-demographics
Age (years), mean (SD) 55.2 (11.7) 50.3 (14.7) 49.5 (11.1)
Female gender, N (%) 24 (55) 32 (65) 17 (65)
BMI, mean (SD) 30.8 (6.3) 29.5 (6.2) 32.5 (8.2)
Current smoker, N (%) 17 (39) 14 (28) 9 (34)
Pain
RMDQ disability score (0–23), mean (SD) 12.5 (5.1) 11.8 (6.0) 11.8 (6.8)
Back pain intensity NRS, mean (SD) 6.6 (2.3) 6.7 (2.2) 6.9 (2.3)
Leg pain intensity, NRS, mean (SD) 6.4 (2.4) 6.1 (2.4) 7.0 (2.4)
Pain below knee, N (%) 30 (71) 28 (61) 21 (84)
Leg pain is worse, N (%) 21 (49) 22 (45) 16 (61)
Duration of current symptomsa
Back pain
Back pain< 6 weeks, N (%) 15 (36) 14 (29) 7 (27)
Back pain 6–12 weeks, N (%) 12 (29) 8 (17) 7 (27)
Back pain > 3 months, N (%) 15 (36) 26 (54) 12 (46)
Leg pain
Leg pain< 6 weeks, N (%) 17 (40) 15 (33) 8 (32)
Leg pain 6–12 weeks, N (%) 15 (36) 9 (20) 8 (32)
Leg pain> 3months, N (%) 10 (24) 22 (48) 9 (36)
aThere was a small proportion of missing data for symptom duration
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were female. Ninety three (78%) were clinically diag-
nosed with sciatica and of these, 44 (47.3%) had MRI
confirmed nerve root compression due to disc pro-
lapse. Table 1 shows the baseline demographics of the
cohort.
None of the biomarkers tested showed any difference
in level between patients with or without clinically con-
firmed sciatica, nor did they show any differences
between sciatica patients with MRI findings of nerve
root compression (n = 44) and those without (n = 49).
Serum IL-6 levels were low or below the level of detec-
tion, and no difference was seen in the levels of IL-6 or
TNFα or any of the other biomarkers between the groups
(Table 2). None of the biomarkers selected were signifi-
cantly associated with either clinically determined sciatica
or sciatica with positive MRI findings, in the multivariate
variable selection procedure or logistic regression analysis.
There was no evidence of significant multicollinearity.
Table 2 Median biomarker levels in those with clinically defined sciatica and in those with and without MRI findings
Biomarker Clinically defined sciatica Clinically defined sciatica plus
MRI changesa
No (n = 26) Yes (n = 93) No (n = 49) Yes (n = 44)
TNFα 11.9 (9.7–13.8) 10.7 (1.0–14.8) 12.39 (1.0–14.74) 9.86 (1.0–14.96)
IL-1β BLD BLD BLD BLD
IL-6 BLD BLD 4.96 (1.6–7.4) 4.21 (0.5–7.7)
IL-33 9.0 (7.2–10.9) 8.0 (6.9–10.4) 9.1(7.9–10.1) 8.8 (7.3–10.1)
IFNγ BLD BLD BLD BLD
TNFRI 5117.1 5087.4 5059.9 5190.3
(4379.9–5692.6) (4525.4–6033.3) (4660.4–5838.9) (4418.2–6113.9)
IL-1RI 1488.8 1469.6 1490.5 1423.9
(1311.8–1620.9) (1273.0–1626.3) (1346.4–1615.8) (1143.8–1654.0)
IL-1RII 6913.9 6985.1 7347.6 6797.3
(5541.3–7819.7) (6099.9–8066.3) (6513.9–8414.0) (5818.4–7825.0)
IL-1Ra 866.3 998.4 974.4 1019.7
(575.8–1267.8) (735.8–1421.6) (693.9–1419.7) (7417.7–1508.9)
CXCL8 2.8 3.6 3.7 4.7
(0.9–3.5) (1.5–6.4) (1.7–6.5) (2.3–7.1)
MCP-1 313.7 257.9 274.3 310.0
(247.7–313.7) (207.8–361.8) (191.1–348.2) (213.6–416.0)
FGFβ BLD BLD BLD BLD
VEGF 42.9 (19.4–62.2) 65.0 (22.0–98.5) 66.2 (27.6–96.9) 63.5 (20.7–123.8)
HGF 265.5 245.9 244.9 245.9
(212.5–351.9) (191.0–321.7) (182.6–315.1) (196.9–315.1)
Ang-2 2164.8 2465.0 2311.2 2870.0
(1637.7–3385.0) (1842.1–3375.4) (1659.9–3070.6) (1921.6–3456.1)
MMP-1 8450.0 7857.2 7344.9 8011.0
(4267.3–13,173.5) (5031.0–15,134.3) (5113.1–12,124.3) (4171.7–24,762.6)
MMP-2 46,778.4 44,214.2 42,714.7 44,418.4
(45,258.0–48,596.9) (37,585.8–50,496.4) (36,594.9–50,419.9) (38,275.4–50,668.8)
MMP-3 13,741.5 12,111.6 12,852.8 11,882.8
(8626.9–22,480.1) (8403.3–18,651.9) (7733.5–18,337.4) (8863.1–18,789.5)
MMP-8 8942.1 7409.5 7842.8 6091.0
(4098.4–11,552.5) (4509.8–12,196.8) (4518.1–10,694.5) (4181.4–13,098.2)
Aggrecan 943.0 922.9 911.2 961.4
(747.4–1302.5) (618.8–1253.4) (624.7–1272.3) (589.5–1243.3)
BLD majority of samples below the limit of detection
aMRI findings of nerve root compression in patients with clinically defined sciatica. (i.e. changes Y/N). Values shown are the median (interquartile range) in pg/ml
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Discussion
LBP and sciatica are common health problems with
significant impact at both the individual level (in terms
of pain and disability) and the health and societal level
(in terms of healthcare costs and work loss). Studies
have suggested a possible inflammatory aetiology in the
development or persistence of sciatic pain, and given the
availability of cytokine inhibitors for treatment of inflam-
matory arthritis, this has prompted research to deter-
mine whether these agents could be effective for sciatica.
Previous studies have confirmed the presence of key cy-
tokines such as TNFα and IL-6 in surgical disc samples,
and recent data have suggested that serum levels of
these cytokines may be elevated in patients with sciatica
symptoms [8–10], although other studies have shown no
association [14].
In this study of patients with low back-related leg pain
seeking primary healthcare, no difference was found in
the levels of TNFα or IL-6 between those with or with-
out either clinically defined sciatica or clinically defined
sciatica with concordant MRI findings. The results of
this study are in contrast to those of Wang [10] who
found elevated levels of TNFα and IL-6 in patients with
severe sciatica (defined as pain level of > 3 on VAS).
However, in part this difference may be explained by the
characteristics of the patients recruited in the study by
Wang et al. [10], as patients were recruited from a spinal
clinic and had a mean symptom duration of 48 weeks.
By contrast, our cohort was recruited from primary care
attenders who had a shorter duration of symptoms, with
over one third of patients having leg pain duration of
less than 6 weeks.
There are a number of strengths and weaknesses that
need to be considered when interpreting the results of
this study. A key strength is that the cohort represents
an unselected population of primary care consulters with
low back-related leg pain and sciatica rather than being
recruited from spinal surgical clinics and as such the re-
sults are likely to be highly generalizable. Furthermore,
patients underwent a standardised clinical assessment
and MRI scan [11], providing confidence in the likely
diagnosis of radicular pain. As all participants in the bio-
marker sub-study were recruited from a single research
clinic, all samples were taken at a similar time of day
thus reducing biological variability.
One of the weaknesses is that biomarker measurements
were made at a single time point only, so we are not able
to determine whether there were fluctuations in the levels
of biomarkers over time (associated with the level of pain
for example. Other hypotheses that may explain our nega-
tive results are that firstly we did not have a group of pain
free controls for comparison (albeit that this was not the
original aim of the study) or that the groups were not suf-
ficiently different to detect differences. Since there are
currently no internationally agreed standard benchmark
serum levels for any of these biomarkers, comparisons
across studies is not possible [15]. Secondly, given
that some of the subgroups were small the study was
underpowered to be able to detect differences in bio-
marker levels between the subgroups. Nevertheless,
the unselected primary care population, who under-
went standardised assessments, ensures that the co-
hort is generalizable. Further longitudinal studies are
required to determine whether cytokine levels become
elevated in those with persistent symptoms rather
than those with a short symptom duration.
Conclusion
In summary, in our primary care cohort of patients with
low back-related leg pain including sciatica, serum
markers associated with inflammation, angiogenesis or
extracellular matrix remodelling do not discriminate be-
tween patients with and without sciatica, or between
those with sciatica with and without obvious evidence of
nerve root compression on MRI. Larger longitudinal
studies are required to determine whether any serum
biomarker levels are associated with persistence of sciat-
ica symptoms or whether other biomarkers could be im-
portant in the pathogenesis and persistence of sciatica.
Appendix
The Milliplex-MAP cytokine assay from Millipore UK was
a custom designed assay based on product HCYTOMAG-
60 K which allows the choice of up to 60 different
cytokines. The MMP assay from R&D Systems was also
custom designed using a Fluorokine MAP Base kit for
MMPs (cat no LMP000) and individual MMP assays
(MMP-1 cat no LMP091, MMP-2 cat no LMP902,
MMP-3 cat no LMP513, MMP-8 cat no LMP908).
Abbreviations
GP: General Practitioner; IFN: Interleukin; IL: Interleukin; LBP: Low back pain;
MCP: Monocyte chemoattractant protein; MMP: Matrix Metalloproteinase;
MRI: Magnetic resonance imaging; REC: Research Ethics Committee;
SD: Standard deviation; TNF: Tumour necrosis factor; VAS: Visual Analogue
Score
Acknowledgements
The authors would like to thank the members of the ATLAS study team, and
all participating patients.
Funding
The study was funded by an NIHR/CNO Clinical Lectureship awarded to K.
Konstantinou. K. Konstantinou was supported by a HEFCE Senior Clinical
Lecturer award. EMH is a NIHR Senior NIHR investigator. This paper presents
independent research funded by the National Institute for Health Research
(NIHR), under its Programme Grants for Applied Research funding scheme:
“Optimal management of spinal pain and sciatica in primary care” (NIHR-RP-
PG-0707-10131). The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health and
Social Care. The study funders had no role in the study design; data
collection, analysis, or interpretation; in the writing of the paper; or in the
decision to submit the paper for publication.
Hider et al. BMC Musculoskeletal Disorders          (2019) 20:202 Page 5 of 6
Availability of data and materials
All data generated or analysed during this study are included in this
published article. The data used in this analysis are owned by The Arthritis
Research UK Primary Care Centre, to which further queries related to data
access may be submitted. The Arthritis Research UK Primary Care Centre has
established data sharing arrangements to support joint publications and
other research collaborations. Applications for access to anonymised data
from our research databases are reviewed by the Centre’s Data Custodian
and Academic Proposal (DCAP) Committee, and a decision regarding access
to the data is made subject to the National Research Ethics Service ethical
approval first provided for the study and to new analysis being proposed.
Consideration to release data will be undertaken in conjunction with journal
publication and/ or funder restrictions that may apply. Further information
on our data sharing procedures can be found on the Centre’s website
(www.keele.ac.uk/pchs/datasharing) or by emailing the Centre’s data
manager (primarycare.datasharing@keele.ac.uk).
Authors’ contributions
SH, KK, EMH and DLM made substantial contributions to conception and
design, KK, JG and DLM made substantial contributions to acquisition of
data. DLM was responsible for analysis and interpretation of data. All authors
been involved in drafting the manuscript or revising it critically for important
intellectual content and have given final approval of the version to be
published.
Ethics approval and consent to participate
The study was approved by the North West- Greater Manchester South
Research Ethics Committee (REC reference number: 12/NW/0173) and all
patients provided written informed consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 6 June 2018 Accepted: 30 April 2019
References
1. Konstantinou K, Hider SL, Jordan JL, Lewis M, Dunn KM, Hay EM. The impact of
low back-related leg pain on outcomes as compared with low back pain
alone: a systematic review of the literature. Clin J Pain. 2013 Jul;29(7):644–54.
2. Valat JP, Genevay S, Marty M, Rozenberg S, Koes B. Sciatica. Best Pract Res
Clin Rheumatol. 2010 Apr;24(2):241–52.
3. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Bowman C,
Hammond A, et al. The treatment of disc-herniation-induced sciatica with
infliximab: one-year follow-up results of FIRST II, a randomized controlled
trial. Spine (Phila Pa 1976). 2006;31(24):2759–66.
4. Genevay S, Finckh A, Zufferey P, Viatte S, Balagué F, Gabay C. Adalimumab
in acute sciatica reduces the long-term need for surgery: a 3-year follow-up
of a randomised double-blind placebo-controlled trial. Ann Rheum Dis.
2012;71(4):560–2.
5. Wang YF, Chen PY, Chang W, Zhu FQ, Xu LL, Wang SL, Chang LY, Luo J, Liu
GJ. Clinical significance of tumor necrosis factor-α inhibitors in the
treatment of sciatica: a systematic review and meta-analysis. PLoS One.
2014;9(7):e103147.
6. Williams NH, Lewis R, Din NU, Matar HE, Fitzsimmons D, Phillips CJ, Sutton
A, Burton K, Hendry M, Nafees S, Wilkinson C. A systematic review and
meta-analysis of biological treatments targeting tumour necrosis factor α
for sciatica. Eur Spine J. 2013;22(9):1921–35.
7. Jing S, Yang C, Zhang X, Wen S, Li Y. Efficacy and safety of etanercept in
the treatment of sciatica: a systematic review and meta-analysis. J Clin
Neurosci. 2017;44:69–74.
8. Andrade P, Hoogland G, Garcia MA, Steinbusch HW, Daemen MA, Visser-
Vandewalle V. Elevated IL-1β and IL-6 levels in lumbar herniated discs in
patients with sciatic pain. Eur Spine J. 2013;22(4):714–20. https://doi.org/10.
1007/s00586-012-2502-x Epub 2012 Sep 27.
9. Pedersen LM, Schistad E, Jacobsen LM, Røe C, Gjerstad J. Serum levels of
the pro-inflammatory interleukins 6 (IL-6) and −8 (IL-8) in patients with
lumbar radicular pain due to disc herniation: a 12-month prospective study.
Brain Behav Immun. 2015;46:132–6.
10. Wang K, Bao JP, Yang S, Hong X, Liu L, Xie XH, Wu XT. A cohort study
comparing the serum levels of pro- or anti-inflammatory cytokines in
patients with lumbar radicular pain and healthy subjects. Eur Spine J. 2016;
25(5):1428–34.
11. Konstantinou K, et al. Clinical course, characteristics and prognostic
indicators in patients presenting with back and leg pain in primary care.
The ATLAS study protocol. BMC Musculoskelet Disord. 2012;13:4.
12. McHenry CE. Computation of a best subset in multivariate analysis. Appl
Stat. 1978;27:291–6.
13. Konstantinou K, Dunn KM, Ogollah R, Lewis M, van der Windt D, Hay EM.
ATLAS Study Team. Prognosis of sciatica and back-related leg pain in
primary care: the ATLAS cohort. Spine J. 2018;18(6):1030-40.
14. Brisby H, Olmarker K, Larsson K, Nutu M, Rydevik B. Proinflammatory
cytokines in cerebrospinal fluid and serum in patients with disc herniation
and sciatica. Eur Spine J. 2002 Feb;11(1):62–6.
15. SS, Smith MS, Reda D, Suffredini AF, McCoy JP Jr. Multiplex bead array
assays for detection of soluble cytokines: comparisons of sensitivity and
quantitative values among kits from multiple manufacturers. Cytometry B
Clin Cytom. 2004;61(1):35–9.
Hider et al. BMC Musculoskeletal Disorders          (2019) 20:202 Page 6 of 6
